Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Nationwide Children's Hospital
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
ICGCT including pure germinoma and MMGCT.
Patients with histologically proven germinoma and MMGCT, including endodermal sinus tumor (yolk sac tumor), embryonal carcinoma, choriocarcinoma and mixed germ cell tumor will be eligible for the study.
Patients with mature/immature teratoma who have tumor marker elevations are eligible on this study.
Patient with ONLY mature and/or immature teratoma are ineligible in the absence of the tumor marker elevations.
You may not be if
Patients with ICGCTs who are newly diagnosed are excluded from the study.
Patients with the diagnosis of mature or immature teratoma in the absence of tumor marker elevations are excluded from the study.
Patients who are pregnant or breastfeeding are excluded from the study.
Patients who have received previously a high dose chemotherapy regimen and autologous transplant are excluded from this study.
Patients who have received gemcitabine, oxaliplatin and/or paclitaxel are excluded from this study.
Clareo Health | Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
